Jaguar Health Subsidiary Napo Pharmaceuticals Inc. Gets FDA Orphan Drug Designation For Crofelemer For Treatment Of Microvillus Inclusion Disease
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=897722
Hyperfine Has Been Granted FDA 510k Clearance For The Swoop Portable MR Imaging System
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K230208
Lucira Health is Soaring Monday: Here Are The Details
Lucira Health Inc (NASDAQ: LHDX) shares are soaring on Monday after the company announced U.S.
Lucy Scientific Discovery Announces First Commercial Sale Of Psilocybin Following Initial Delivery Of DMT And 5-MeO-DMT To Hadassah BrainLabs
Lucy Scientific Discovery Inc. ("Lucy" or the "Company") (NASDAQ:LSDI), an early-stage manufacturing company that is focused on becoming the premier research, development, and manufacturing
SciSparc Signs Agreement For The Supply Of CBD-Rich Cannabis Oil For Its Clinical Trial On Children With Autism Spectrum Disorder
The cannabis oil will be used as a part of the Company's proprietary SCI-210 treatment combination of CBD and CannAmide™
FDA Authorizes Lucira’s Over-the-Counter At-Home Test To Detect Both Influenza, COVID-19 Viruses
https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-over-counter-home-test-detect-both-influenza-and-covid-19-viruses
FDA Slams Break On Fulcrum Therapeutics’ Sickle Cell Disease Study, Shares Plummet
The FDA verbally informed Fulcrum Therapeutics Inc (NASDAQ:FULC) that it has issued a full clinical hold regarding the Investigational New Drug (IND)…
‘New Phase 3 Data Presented At WORLDSymposium Reinforce Nexviazyme As Potential New Standard Of Care For All People Living With Late-Onset Pompe Disease’
New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with
Additional Interim Data From Phase I/II Trial Of REGENXBIO’S RGX-111 For The Treatment Of Severe MPS I Presented At WORLDSymposium
RGX-111 is an investigational AAV Therapeutic for the treatment of severe MPS I that is part of REGENXBIO's clinical-stage pipeline of neurodegenerative disease programs
RGX-111, a potential one-time gene
